Company Overview - Yuyuan Group Co., Ltd. is located at 2 Fuxing East Road, Huangpu District, Shanghai, established on November 25, 1987, and listed on September 2, 1992 [2] - The company's main business includes gold and jewelry sales, catering and pharmaceutical business, and real estate development [2] - Revenue composition: 76.09% from industrial operations, 17.20% from property development and sales, and 6.71% from commercial comprehensive operations and property services [2] Stock Performance - Yuyuan's stock price has decreased by 6.10% year-to-date, with a 4.25% drop over the last five trading days and a 5.02% decline over the last 20 days, while it increased by 6.35% over the last 60 days [2] - As of September 23, the stock price was 5.86 CNY per share, with a market capitalization of 22.836 billion CNY [1] Financial Performance - For the first half of 2025, Yuyuan reported revenue of 19.112 billion CNY, a year-on-year decrease of 30.68%, and a net profit attributable to shareholders of 62.814 million CNY, down 94.50% year-on-year [2] - The company has distributed a total of 10.042 billion CNY in dividends since its A-share listing, with 2.832 billion CNY distributed over the past three years [3] Shareholder Information - As of June 30, the number of shareholders was 83,300, a decrease of 2.66% from the previous period, with an average of 46,702 circulating shares per shareholder, an increase of 2.73% [2] Market Activity - On September 23, the net outflow of main funds was 6.8864 million CNY, with significant selling activity amounting to 7.2643 million CNY, representing 42.15% of total transactions [1]

Core Viewpoint - Aimeike's stock price has shown volatility, with a recent decline of 2.00% and a total market capitalization of 55.374 billion yuan, reflecting a mixed performance in the market [1] Financial Performance - For the first half of 2025, Aimeike reported a revenue of 1.299 billion yuan, a year-on-year decrease of 21.59%, and a net profit attributable to shareholders of 789 million yuan, down 29.57% year-on-year [2] - Cumulative cash dividends since Aimeike's A-share listing amount to 3.887 billion yuan, with 3.012 billion yuan distributed over the past three years [3] Shareholder Information - As of September 10, 2025, Aimeike had 54,600 shareholders, a decrease of 0.91% from the previous period, with an average of 3,822 circulating shares per shareholder, an increase of 0.92% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 6.9808 million shares (a decrease of 1.0906 million shares), and Huabao CSI Medical ETF, holding 5.0610 million shares (an increase of 0.0607 million shares) [3] Stock Performance - Aimeike's stock has increased by 2.40% year-to-date, but has seen a decline of 5.70% over the last five trading days and 5.19% over the last twenty days [1] - The stock's trading volume on September 22 was 188 million yuan, with a turnover rate of 0.49% [1] Business Overview - Aimeike, established on June 9, 2004, specializes in the research, production, and sales of biomedical soft tissue repair materials, with its main revenue sources being solution injection products (57.27%) and gel injection products (37.97%) [1] - The company operates within the beauty care and medical aesthetics industry, focusing on medical consumables [1]

Core Viewpoint - Huaxi Bio's stock price has shown fluctuations, with a year-to-date increase of 8.82% but a recent decline of 7.48% over the past five trading days, indicating potential volatility in investor sentiment [2]. Company Overview - Huaxi Bio, established on January 3, 2000, and listed on November 6, 2019, is located in Jinan, Shandong Province. The company specializes in microbial fermentation and cross-linking technologies, developing bioactive materials that contribute to human health [2]. - The company has a comprehensive business model that spans from raw materials to medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing companies, medical institutions, and end-users [2]. Revenue Composition - The revenue composition of Huaxi Bio is as follows: 40.34% from skin science innovation transformation, 29.76% from medical terminal products, 27.70% from raw materials, and 2.17% from other sources [2]. Financial Performance - For the first half of 2025, Huaxi Bio reported a revenue of 2.261 billion yuan, a year-on-year decrease of 19.57%, and a net profit attributable to shareholders of 221 million yuan, down 35.38% year-on-year [2]. Shareholder Information - As of June 30, 2025, Huaxi Bio had 32,500 shareholders, an increase of 1.78% from the previous period. The average circulating shares per person decreased by 1.75% to 14,799 shares [2]. - The company has distributed a total of 1.138 billion yuan in dividends since its A-share listing, with 528 million yuan distributed over the past three years [3]. Institutional Holdings - The top ten circulating shareholders include notable ETFs, with Huaxia SSE Sci-Tech Innovation Board 50 ETF holding 10.6429 million shares, a decrease of 244,800 shares from the previous period. Other ETFs have shown varying changes in their holdings [3].

Core Viewpoint - Renhe Pharmaceutical's stock price has shown fluctuations, with a recent decline of 2.00% on September 19, 2023, and a total market capitalization of 8.918 billion yuan [1] Group 1: Stock Performance - Year-to-date, Renhe Pharmaceutical's stock price has increased by 13.55%, but it has seen a decline of 0.62% over the last five trading days and 4.21% over the last twenty days [2] - The stock has experienced a 17.53% increase over the last sixty days [2] Group 2: Financial Performance - For the first half of 2025, Renhe Pharmaceutical reported a revenue of 1.975 billion yuan, a year-on-year decrease of 16.46%, and a net profit attributable to shareholders of 290 million yuan, down 13.87% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.962 billion yuan, with 770 million yuan distributed over the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Renhe Pharmaceutical was 104,400, a decrease of 2.76% from the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with both increasing their holdings compared to the previous period [3]

Core Viewpoint - Mingchen Health's stock price has experienced a decline of 6.34% year-to-date, with a recent drop of 2.04% on September 19, 2023, indicating potential challenges in market performance [1][2]. Company Overview - Mingchen Health, established on December 14, 1994, and listed on December 18, 2017, is located in the Lian Nan Industrial Zone, Chenghai District, Shantou City, Guangdong Province. The company specializes in the research, production, and sales of health care products, including shampoos, conditioners, shower gels, gel water, and skincare products [2]. - The company's revenue composition is as follows: 76.84% from online games, 23.09% from daily chemical products, and 0.07% from other sources [2]. Financial Performance - For the first half of 2025, Mingchen Health reported a revenue of 712 million yuan, reflecting a year-on-year growth of 7.07%. However, the net profit attributable to shareholders decreased by 31.97% to 41.06 million yuan [2]. - Since its A-share listing, Mingchen Health has distributed a total of 151 million yuan in dividends, with 46.57 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Mingchen Health increased by 2.88% to 18,800, with an average of 14,063 circulating shares per person, a decrease of 2.80% [2]. - Notable institutional holdings include Huaxia Industry Prosperity Mixed Fund, which is the fourth largest shareholder with 5.2765 million shares, an increase of 1.6392 million shares from the previous period [3].

Company Overview - Nobon Co., Ltd. is located in Yuhang Economic and Technological Development Zone, Hangzhou, Zhejiang Province, and was established on November 27, 2002. The company was listed on February 22, 2017. Its main business involves the research, production, and sales of differentiated and personalized water-jet non-woven materials and their products, as well as the development, production, and sales of disposable hygiene products such as wet wipes [1]. Financial Performance - As of June 30, 2025, Nobon Co., Ltd. achieved an operating income of 1.34 billion yuan, representing a year-on-year growth of 33.35%. The net profit attributable to the parent company was 65.33 million yuan, reflecting a year-on-year increase of 48.33% [2]. - The company has distributed a total of 263 million yuan in dividends since its A-share listing, with 124 million yuan distributed in the last three years [3]. Stock Performance - On September 18, Nobon Co., Ltd. experienced a decline of 2.07%, with a stock price of 19.91 yuan per share, a trading volume of 26.43 million yuan, and a turnover rate of 0.74%. The total market capitalization is 3.534 billion yuan [1]. - Year-to-date, the stock price has increased by 57.27%, while it has decreased by 3.72% over the last five trading days and by 3.58% over the last 20 days. In contrast, the stock has risen by 16.16% over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders of Nobon Co., Ltd. was 11,200, a decrease of 33.28% from the previous period. The average number of circulating shares per person increased by 49.88% to 15,866 shares [2]. - Among the top ten circulating shareholders, Southern Growth Mixed A (202003) is the fourth largest with 6.1966 million shares, and Huazheng Anxin Consumer Mixed A (519002) is the seventh largest with 2.0018 million shares, both being new shareholders [3]. Industry Classification - Nobon Co., Ltd. is classified under the Shenwan industry category of textile and apparel - textile manufacturing - other textiles. The company is associated with various concept sectors, including cosmetics, multiple births, small-cap stocks, Xiaohongshu concept, and pet economy [1].

Group 1 - The stock price of Huaye Spice fell by 2.01% on September 18, reaching 28.77 CNY per share, with a trading volume of 19.73 million CNY and a turnover rate of 1.56%, resulting in a total market capitalization of 2.15 billion CNY [1] - Year-to-date, Huaye Spice's stock price has increased by 53.93%, but it has seen a decline of 4.89% over the last five trading days, 11.64% over the last 20 days, and 1.13% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on June 12 [1] Group 2 - As of June 30, the number of shareholders for Huaye Spice reached 12,800, an increase of 77.14% compared to the previous period, while the average circulating shares per person decreased by 43.31% to 3,415 shares [2] - For the first half of 2025, Huaye Spice reported operating revenue of 192 million CNY, a year-on-year increase of 11.05%, and a net profit attributable to shareholders of 20.99 million CNY, reflecting a year-on-year growth of 52.76% [2] - Since its A-share listing, Huaye Spice has distributed a total of 26.38 million CNY in dividends, with 11.18 million CNY distributed over the past three years [3] Group 3 - As of June 30, 2025, the top ten circulating shareholders of Huaye Spice saw a change, with CITIC Prudential Multi-Strategy Mixed Fund (LOF) A exiting the list [3]

Company Overview - Shanghai Shunhao New Materials Technology Co., Ltd. was established on December 21, 2004, and listed on March 18, 2011. The company is located at 200 Zhenchen Road, Putuo District, Shanghai [2] - The main business includes research, production, processing, and sales of vacuum aluminum-coated paper, composite film paper, white cardboard, printed products, and cigarette polypropylene fiber bundles [2] - The revenue composition is as follows: printed products 48.07%, aluminum-coated paper 30.03%, others (supplement) 8.51%, composite film paper 5.56%, others 3.93%, optical anti-counterfeiting film 2.02%, new tobacco 1.65%, and white cardboard 0.23% [2] Financial Performance - For the first half of 2025, the company achieved operating revenue of 620 million yuan, a year-on-year decrease of 12.19%. The net profit attributable to the parent company was 33.30 million yuan, a year-on-year increase of 23.11% [2] - Since its A-share listing, the company has distributed a total of 427 million yuan in dividends, with 68.81 million yuan distributed in the last three years [3] Stock Performance - On September 17, the stock price of Shunhao fell by 2.03%, trading at 7.24 yuan per share, with a total market capitalization of 7.674 billion yuan [1] - Year-to-date, the stock price has increased by 141.25%, but it has decreased by 5.73% in the last five trading days and 14.72% in the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on July 22, where it recorded a net buy of -21.52 million yuan [1] Shareholder Information - As of June 30, the number of shareholders was 46,100, a decrease of 11.52% from the previous period. The average circulating shares per person increased by 13.01% to 23,011 shares [2]

Company Overview - Angel Yeast Co., Ltd. is located at 168 Chengdong Avenue, Yichang City, Hubei Province, established on March 25, 1998, and listed on August 18, 2000. The company primarily engages in the development, production, and operation of yeast, yeast derivatives, and related biological products [1] - The main business revenue composition includes yeast and related industries at 90.62%, other at 7.89%, and packaging materials at 4.07% [1] Financial Performance - For the first half of 2025, Angel Yeast achieved operating revenue of 7.899 billion yuan, a year-on-year increase of 10.10%, and a net profit attributable to shareholders of 799 million yuan, a year-on-year increase of 15.66% [2] - Since its A-share listing, Angel Yeast has cumulatively distributed cash dividends amounting to 3.961 billion yuan, with 1.341 billion yuan distributed in the last three years [3] Stock Market Activity - As of September 17, Angel Yeast's stock price decreased by 2.06%, trading at 39.51 yuan per share, with a total market capitalization of 34.3 billion yuan [1] - Year-to-date, the stock price has increased by 11.30%, with a recent decline of 3.80% over the last five trading days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on March 5, where it recorded a net buy of -136 million yuan [1] Shareholder Information - As of June 30, the number of shareholders for Angel Yeast was 63,900, a decrease of 5.74% from the previous period, with an average of 13,411 circulating shares per person, an increase of 6.42% [2] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 36.9082 million shares, an increase of 1.3394 million shares from the previous period [3]

Core Viewpoint - Huaxi Biological has shown a significant increase in stock price and market performance, despite a decline in revenue and net profit in the first half of 2025 [1][2]. Company Overview - Huaxi Biological Technology Co., Ltd. was established on January 3, 2000, and went public on November 6, 2019. The company is located in Jinan, Shandong Province, and specializes in microbial fermentation and cross-linking technology platforms [1]. - The company has developed a full industry chain business system that includes raw materials, medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing enterprises, medical institutions, and end users [1]. Financial Performance - As of July 31, 2025, Huaxi Biological reported a revenue of 2.261 billion yuan, a year-on-year decrease of 19.57%, and a net profit attributable to shareholders of 221 million yuan, down 35.38% year-on-year [2]. - The company has distributed a total of 1.138 billion yuan in dividends since its A-share listing, with 528 million yuan distributed in the last three years [3]. Stock Performance - On September 15, Huaxi Biological's stock price increased by 2.01%, reaching 60.30 yuan per share, with a total market capitalization of 29.045 billion yuan [1]. - The stock has seen an 18.40% increase year-to-date, with a 0.50% rise over the last five trading days, a 12.00% increase over the last 20 days, and a 19.26% increase over the last 60 days [1]. Shareholder Information - As of July 31, 2025, the number of shareholders for Huaxi Biological was 32,500, an increase of 1.78% from the previous period, with an average of 14,799 circulating shares per shareholder, a decrease of 1.75% [2]. - Major shareholders include various ETFs, with notable changes in holdings among the top ten circulating shareholders [3].